Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure

(2014) S. J. Garcés-Eisele et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Comparative Effectiveness Questions in Oncology

(2014) Sham Mailankody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Valproic acid pathway

(2013) Yogita Ghodke-Puranik et al.   Pharmacogenetics and Genomics

Cancer drug discovery by repurposing: teaching new tricks to old dogs

(2013) Subash C. Gupta et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Induction of a trophoblast-like phenotype by hydralazine in the p19 embryonic carcinoma cell line

(2012) Cliona M. O'Driscoll et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

DNA methylation profiling in the clinic: applications and challenges

(2012) Holger Heyn et al.   NATURE REVIEWS GENETICS

Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers

(2012) S. Seisenberger et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells

(2012) Myrna Candelaria et al.   PLoS One

Cancer Chemoprevention by Targeting the Epigenome

(2011) Joseph Huang et al.   CURRENT DRUG TARGETS

Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype

(2011) A. Gonzalez-Fierro et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes

(2011) Yu-Hsun Kao et al.   LABORATORY INVESTIGATION

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

(2011) S. Ito et al.   SCIENCE

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

(2011) Andrea Kuendgen et al.   Clinical Epigenetics

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

(2010) Myrna Candelaria et al.   ANNALS OF HEMATOLOGY

Interplay between microRNAs and the epigenetic machinery: An intricate network

(2010) Marilena V. Iorio et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Structure and Function of Mammalian DNA Methyltransferases

(2010) Renata Zofia Jurkowska et al.   CHEMBIOCHEM

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

(2010) Jaime Coronel et al.   MEDICAL ONCOLOGY

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

(2009) Dirk Kuck et al.   BIOORGANIC & MEDICINAL CHEMISTRY

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

(2009) R L Jones et al.   BRITISH JOURNAL OF CANCER

Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model

(2009) C. M. Lyon et al.   CARCINOGENESIS

Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1

(2009) Narender Singh et al.   ChemMedChem

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

(2009) Steven D. Gore   LEUKEMIA RESEARCH

Association between CpG Island Methylation of the WWOX Gene and Its Expression in Breast Cancers

(2009) X. Wang et al.   TUMOR BIOLOGY

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

(2008) Yinhong Song et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells

(2008) Alice Y.S. Law et al.   EXPERIMENTAL CELL RESEARCH

The prince and the pauper. A tale of anticancer targeted agents

(2008) Alfonso Dueñas-González et al.   Molecular Cancer